{"id":532034,"date":"2021-02-26T21:24:01","date_gmt":"2021-02-26T21:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=532034"},"modified":"2021-02-26T21:24:01","modified_gmt":"2021-02-26T21:24:01","slug":"endstage-renal-disease-esrd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/endstage-renal-disease-esrd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_532034.html","title":{"rendered":"End-Stage Renal Disease (ESRD) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"End-Stage Renal Disease (ESRD) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"End-Stage Renal Disease (ESRD) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><strong>End-stage renal disease (ESRD)<\/strong> also known as end-stage renal failure is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. In this condition, kidneys are only functioning at 10&ndash;15% of their normal capacity. A patient with end-stage renal failure must receive dialysis or kidney transplantation in order to survive for more than a few weeks.<\/p>\n<p style=\"text-align: justify;\">Diabetic nephropathy (DN) is one of the most common complications of diabetes and the leading cause of the end-stage renal disease (ESRD). Approximately 30&ndash;40% of diabetes mellitus patients in the world progress to ESRD, which emphasizes the effect of genetic factors on DN.<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at: <\/strong><br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/end-stage-renal-disease-esrd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/end-stage-renal-disease-esrd-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">The <strong>End-Stage Renal Disease (ESRD) market report<\/strong> also covers emerging drugs, current treatment practices, End-Stage Renal Disease (ESRD) market share of the individual therapies, current and forecasted End-Stage Renal Disease (ESRD) Market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>End-Stage Renal Disease (ESRD) treatment practice<\/strong><strong>\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"End-Stage Renal Disease (ESRD) Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/5c3011d11adc9b826d84ada77c20ab29.jpg\" alt=\"End-Stage Renal Disease (ESRD) Market\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>End-Stage Renal Disease (ESRD) Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">ESRD is more common in men than women; however, statistics vary little across different regions. Based on the US Renal Data System (USRDS) annual data report, the <strong>prevalence of chronic renal failure<\/strong> between the years 2007 and 2011 was higher in women (15.1%) than in men (12.1%). However, in the most recent US Renal Data System, 57.8% of the patients with a new-onset ESRD were men<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the National Center for Chronic Disease Prevention and Health Promotion, about 15% of adults in the US are estimated to have chronic kidney disease. <strong>Chronic kidney disease<\/strong> can often be treated before it progresses to end-stage renal failure or leads to other health problems<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The study conducted by Abbasi et al., titled &ldquo;End-stage renal disease&rdquo; estimates that the <strong>prevalence of ESRD in the US<\/strong> in 2007 was 1,698 cases per million population. In 2007, Japan also observed a relatively high prevalence, i.e., 2,060 cases per million population of ESRD, which included only people receiving maintenance dialysis<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">The Center for Disease Control and Prevention (CDC) estimated that as of December 2016, 0.7 million patients were being treated for end-stage renal disease (ESRD) in the United States, giving a point prevalence of 2,206 per million population; the prevalence of dialysis treatment was 1,553 per million, whereas the prevalence of functioning kidney transplant was 653 per million.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of End-Stage Renal Disease (ESRD) Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides an in-depth analysis of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>End-Stage Renal Disease (ESRD) Market Size and Share<\/strong><\/a>, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The End-Stage Renal Disease (ESRD) market report will help in developing business strategies by understanding the <strong>End-Stage Renal Disease (ESRD) Market trends &amp; developments<\/strong>, key players, and future market competition that will shape and drive the End-Stage Renal Disease (ESRD) market in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The End-Stage Renal Disease (ESRD) market report covers <strong>End-Stage Renal Disease (ESRD) current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in 7 MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the <strong>End-Stage Renal Disease (ESRD) market<\/strong> in terms of market drivers &amp; barriers, Unmet Needs, market opportunities, patient population,&nbsp; comparative analysis of pipeline products with detailed clinical profiles, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>End-Stage Renal Disease (ESRD) Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>End-Stage Renal Disease (ESRD) market outlook<\/strong> section of the report helps to build a detailed comprehension of the historic, current and forecasted End-Stage Renal Disease (ESRD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>End-Stage Renal Disease (ESRD) market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>End-Stage Renal Disease (ESRD) Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>End-Stage Renal Disease (ESRD) epidemiology<\/strong> section covers insights about the historical and current End-Stage Renal Disease (ESRD) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>End-Stage Renal Disease (ESRD) Drugs Uptake and Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>End-Stage Renal Disease (ESRD) Drugs<\/strong> Uptake section focuses on the rate of uptake of the potential drugs recently launched in the End-Stage Renal Disease (ESRD) market or expected to get launched in the market during the study period. The analysis covers <strong>End-Stage Renal Disease market<\/strong> uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">End-Stage Renal Disease (ESRD) market size<\/a> is expected to increase during the forecast period owing to the growing prevalence of the disease in the 7MM.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>End-Stage Renal Disease (ESRD) companies:<\/strong><br \/>Aronora<br \/>Merck<br \/>Rockwell Medical Technologies<br \/>Dynavax Technologies Corporation<br \/>And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>End-Stage Renal Disease (ESRD) therapies covered in the report include:<\/strong><br \/>Intravenous Triferic<br \/>AB002<br \/>MK-2060<br \/>And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. End-Stage Renal Disease (ESRD) Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. End-Stage Renal Disease (ESRD) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. End-Stage Renal Disease (ESRD) Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. End-Stage Renal Disease (ESRD) Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. End-Stage Renal Disease (ESRD) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. End-Stage Renal Disease (ESRD) Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. End-Stage Renal Disease (ESRD) Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of End-Stage Renal Disease (ESRD) Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. End-Stage Renal Disease (ESRD) Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. End-Stage Renal Disease (ESRD) Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. End-Stage Renal Disease (ESRD) Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. End-Stage Renal Disease (ESRD) Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. End-Stage Renal Disease (ESRD) Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the End-Stage Renal Disease (ESRD) Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. End-Stage Renal Disease (ESRD) Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. End-Stage Renal Disease (ESRD) Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><br \/><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-epidemiology-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\">End-Stage Renal Disease (ESRD) Epidemiology Forecast<br \/><\/a><\/strong>DelveInsight&#8217;s End-Stage Renal Disease (ESRD) &#8211; Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of End-Stage Renal Disease (ESRD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;About DelveInsight<\/strong><br \/><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=endstage-renal-disease-esrd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd. 2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=endstage-renal-disease-esrd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/endstage-renal-disease-esrd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_532034.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-532034","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=532034"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532034\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=532034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=532034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=532034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}